Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS

Eisuke Adachi; Makoto Saito; Michiko Koga; Takeya Tsutsumi; Hiroshi Yotsuyanagi

doi:10.2169/internalmedicine.0485-22

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS

Eisuke Adachi, Makoto Saito, Michiko Koga, Takeya Tsutsumi, Hiroshi Yotsuyanagi

著者情報

キーワード: prolonged COVID-19, HIV/AIDS, Persistent viral shedding, passive immunity, monoclonal antibody therapy, sotrovimab

ジャーナルオープンアクセス早期公開

論文ID: 0485-22

DOI https://doi.org/10.2169/internalmedicine.0485-22

この記事には本公開記事があります。

The final version of this article is now available: Vol. 61 (2022), No. 22 pp. 3459-3462

詳細

抄録

Persistent viral shedding or prolonged COVID-19 symptom is one of unresolved problem in immunocompromised individuals. We herein report an HIV/AIDS patient with Pneumocystis jirovecii pneumonia and prolonged COVID-19, possibly due to immune reconstitution inflammatory syndrome. His viral shedding and COVID-19 symptoms persisted for 39 days but were promptly resolved following sotrovimab monoclonal antibody therapy. This case suggests that prolonged COVID-19 and persistent viral shedding due to severe cellular immunodeficiency can occur in patients with SARS-CoV-2 omicron infection and that sotrovimab is effective in the treatment of prolonged COVID-19 caused by omicron/BA.1.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）